M. Kraus & Co trimmed its position in Metlife Inc (NYSE:MET) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,893 shares of the financial services provider’s stock after selling 2,725 shares during the quarter. Metlife comprises 2.4% of M. Kraus & Co’s investment portfolio, making the stock its 23rd biggest position. M. Kraus & Co’s holdings in Metlife were worth $4,039,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of MET. Beach Investment Management LLC. acquired a new position in Metlife in the 2nd quarter valued at about $1,471,000. Fiduciary Trust Co. boosted its holdings in Metlife by 15.1% in the 2nd quarter. Fiduciary Trust Co. now owns 12,077 shares of the financial services provider’s stock valued at $664,000 after purchasing an additional 1,580 shares during the last quarter. WMS Partners LLC boosted its holdings in Metlife by 4.4% in the 2nd quarter. WMS Partners LLC now owns 4,429 shares of the financial services provider’s stock valued at $243,000 after purchasing an additional 188 shares during the last quarter. Freestone Capital Holdings LLC boosted its holdings in Metlife by 3.1% in the 2nd quarter. Freestone Capital Holdings LLC now owns 22,746 shares of the financial services provider’s stock valued at $1,250,000 after purchasing an additional 678 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its holdings in Metlife by 114.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 25,375 shares of the financial services provider’s stock valued at $1,394,000 after purchasing an additional 13,560 shares during the last quarter. Institutional investors own 76.27% of the company’s stock.
In other Metlife news, insider Christopher G. Townsend sold 82,731 shares of the stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $54.60, for a total value of $4,517,112.60. Following the sale, the insider now directly owns 49,660 shares of the company’s stock, valued at approximately $2,711,436. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Christopher G. Townsend sold 55,712 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $54.29, for a total transaction of $3,024,604.48. Following the completion of the sale, the insider now directly owns 25,181 shares in the company, valued at $1,367,076.49. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.
Metlife (NYSE:MET) last announced its earnings results on Wednesday, November 1st. The financial services provider reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.19. Metlife had a negative net margin of 0.75% and a positive return on equity of 8.81%. The firm had revenue of $16.10 billion for the quarter, compared to the consensus estimate of $15.47 billion. During the same period in the prior year, the firm earned $1.28 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. analysts predict that Metlife Inc will post 4.42 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Monday, February 5th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Friday, February 2nd. Metlife’s payout ratio is currently 347.83%.
MET has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Metlife from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Thursday, November 9th. ValuEngine lowered shares of Metlife from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 9th. Sandler O’Neill lowered shares of Metlife from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Wells Fargo & Co set a $62.00 price objective on shares of Metlife and gave the stock a “buy” rating in a report on Thursday, December 14th. Finally, Morgan Stanley upped their price objective on shares of Metlife from $54.00 to $55.00 and gave the stock an “equal weight” rating in a report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Metlife presently has an average rating of “Hold” and an average price target of $57.77.
MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.